Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propene SCHEMBL28006036 | 0.91 | POLB (0.38) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL27501838 | 0.83 | POLB (0.43) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL2992966 | 0.83 | CYP3A4 (0.40) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL14671697 | 0.81 | CYP3A4 (0.42) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL14671389 | 0.81 | LMNA (0.39) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL9617315 | 0.81 | LMNA (0.39) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL365852 | 0.81 | CYP3A4 (0.39) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL16761024 | 0.79 | CYP3A4 (0.41) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL24142138 | 0.78 | CYP3A4 (0.37) | POLBCYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL17937995 | 0.77 | POLB (0.46) | POLBCYP3A4CYP2C9CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882030-B1 | NON-AQUEOUS ELECTROLYTE AND ENERGY STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2017-06-21 | — | — | EP | claimed |
| EP-2698859-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND ELECTRICITY-STORAGE DEVICE USING THE SAME | UBE INDUSTRIES (JP) | 2016-07-27 | — | — | EP | claimed |
| EP-2882030-A1 | NON-AQUEOUS ELECTROLYTE AND POWER STORAGE DEVICE USING SAME | Ube Industries, Ltd. (JP) | 2015-06-10 | — | — | EP | claimed |
| CN-101768114-B | Synthesis method of 4-substituted-3-fluorine-2-quinolone | UNIV SOUTHWEST | 2011-07-20 | — | — | CN | claimed |
| CN-120117999-A | Fluorotranilast derivatives and medical application thereof | 中国药科大学 | 2025-06-10 | — | — | CN | disclosed |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | VORONOI INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| CN-118946557-A | Heteroaryl derivatives and uses thereof | 株式会社沃若诺伊 | 2024-11-12 | — | — | CN | disclosed |
| CN-118488952-A | Substituted quinoline derivatives | 安斯泰来制药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-0402246-B1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL UCLAF (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0601573-A1 | Alpha-phosphonocarboxylate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5312814-A | Antilipemic agents or anticholesterol agents | BRISTOL-MYERS SQUIBB CO. (US) | 1994-05-17 | — | — | US | disclosed |
| EP-0402246-A1 | Thiazolylalkoxyacrylates, process for their preparation, their use as fungicides and intermediates in their preparation | ROUSSEL-UCLAF (FR) | 1990-12-12 | — | — | EP | disclosed |
| US-4906663-A | 6-fluoroprostaglandins | ASAHI GLASS COMPANY, LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0312055-A2 | 6-Fluoroprostaglandins | ASAHI GLASS COMPANY LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | POLB 4412/4885CYP3A4 1028/4885CYP2C9 1493/4885 |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | IDH1, IDH2, IDH3A | POLB 1098/4885CYP3A4 916/4885CYP2C9 750/4885 |
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | POLB 4491/4885CYP3A4 1553/4885CYP2C9 3729/4885 |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | ERBB2, ERBB3, EGFR | POLB 3671/4885CYP3A4 249/4885CYP2C9 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.